Hematol Oncol Clin North Am. 1991 Apr;5(2):267-80. Unique Identifier :
Three hematopoietic stimulants have been used in patients with HIV
infection and a variety of AIDS-related complications. Both G-CSF and
GM-CSF have demonstrated the ability to correct leukopenia related to
HIV infection and ameliorate the drug-related myelosuppressive effects
of zidovudine, trimethoprim/sulfamethoxazole, ganciclovir, and, in the
case of GM-CSF, alpha-interferon, and cancer chemotherapies.
Erythropoietin has been successfully used to ameliorate the anemia
associated with HIV infection and zidovudine therapy. Treatment with
these hematopoietic stimulants is very well tolerated with minimal
toxicity. Of the granulocyte stimulants, G-CSF appears to induce fewer
side effects than GM-CSF in trials conducted to date. Future trials
demonstrating that the amelioration of hematopoietic suppression by the
colony-stimulating factors results in increased clinical response rates
and improved survival are necessary to fully assess the value of this
approach in the care of HIV-infected patients.
Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY Drug
Therapy, Combination Erythropoietin/THERAPEUTIC USE
Granulocyte-Macrophage Colony-Stimulating Factor/THERAPEUTIC USE
Hematopoietic Cell Growth Factors/*THERAPEUTIC USE Human HIV
Infections/*COMPLICATIONS/DRUG THERAPY Lymphoma, Non-Hodgkin's/ETIOLOGY
Sarcoma, Kaposi's/ETIOLOGY Support, Non-U.S. Gov't Support, U.S.
Gov't, P.H.S. Zidovudine/ADVERSE EFFECTS JOURNAL ARTICLE REVIEW